The key for me is the diversity of the revenue str

The key for me is the diversity of the revenue streams. Having one product that is new and growing is not like have 8 products new and growing even if the numbers arethe same. Some will gain traction faster. Some will take a while, and one or two might blow up. But by being diverse you open yourself to being much more stable and predictable. Having to wait on Phentermine API sucks but we are still pending 2 more launches...plus more products.

Plus a lot of other things. I go by the direction of the company.

Also agree on your list for the CC. HITKs generic probably won't be discussed in detail but I think that is one to watch still.